<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983255</url>
  </required_header>
  <id_info>
    <org_study_id>1986-008</org_study_id>
    <secondary_id>TR701-107</secondary_id>
    <nct_id>NCT00983255</nct_id>
  </id_info>
  <brief_title>Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)</brief_title>
  <acronym>IV/SAD/MAD</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Single &amp; Multiple Ascending Dose, Safety, Tolerability, &amp; PK Study of an IV Form of TR-701 Free Acid &amp; an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of&#xD;
      single rising and multiple rising IV doses of TR-701 FA and to determine the absolute&#xD;
      bioavailability of oral TR-701 FA following single oral and IV dose administrations in&#xD;
      healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAD/Part A.&#xD;
&#xD;
        -  All subjects in the Pilot Cohort will receive a single infusion of 50 mg TR-701 FA for&#xD;
           injection in 250 cc of saline over 180 minutes.&#xD;
&#xD;
        -  Subjects in Cohort 1 will be randomized to receive a single infusion of placebo or 100&#xD;
           mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.&#xD;
&#xD;
        -  Subjects in Cohort 2 will be randomized to receive a single infusion of placebo or 200&#xD;
           mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.&#xD;
&#xD;
        -  Subjects in Cohort 3 will be randomized to receive a single infusion of placebo or 400&#xD;
           mg of TR-701 FA for injection in 250 or 500 cc of saline over 60 or 120 minutes.&#xD;
&#xD;
      MAD/Part B&#xD;
&#xD;
        -  Subjects in Cohort 4 will be randomized to receive once daily infusions of placebo or&#xD;
           200 mg of TR-701 FA for injection in 250 cc of saline over 60 minutes for 7 days.&#xD;
&#xD;
        -  Subjects in Cohort 5 will be randomized to receive once daily infusions of placebo or&#xD;
           300 mg of TR-701 FA for injection in 250 cc of saline over 60 minutes for 7 days.&#xD;
&#xD;
      BA/Part C&#xD;
&#xD;
        -  Subjects in Cohort 6 will receive a single 60 minute infusion of 200 mg TR-701 FA for&#xD;
           injection in 250 cc of saline and a singe oral dose of 200 mg TR-701 FA tablet in an&#xD;
           open-label crossover design.&#xD;
&#xD;
      Venous Tolerability/Part D&#xD;
&#xD;
      - Subjects in Cohort 8 will receive once daily 60 minute infusions of 200 mg TR-701 FA for&#xD;
      injection in 250 cc of saline for 3 days and once daily placebo infusions for 3 daysin a&#xD;
      blinded crossover design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of TR-701 and its microbiologically active moiety TR-700 after single and multiple IV doses of TR-701 FA</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>SAD/ Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD / Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bioavailability / Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous Tolerability/ Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA for injection, 200 mg/vial</intervention_name>
    <description>TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 &amp; 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D</description>
    <arm_group_label>Bioavailability / Part C</arm_group_label>
    <arm_group_label>MAD / Part B</arm_group_label>
    <arm_group_label>SAD/ Part A</arm_group_label>
    <arm_group_label>Venous Tolerability/ Part D</arm_group_label>
    <other_name>Torezolid Phospate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA tablets</intervention_name>
    <description>TR-701 FA will be given once orally as a 200 mg tablet in Part C.</description>
    <arm_group_label>Bioavailability / Part C</arm_group_label>
    <other_name>Torezolid Phosphate Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  in good health&#xD;
&#xD;
          -  body mass index of 20 to 29.9 kg/m2&#xD;
&#xD;
          -  female subjects must be post menopausal for at least 1 year, surgically sterile,&#xD;
             abstinent or agree to use an effective method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history or clinical manifestation of any clinically significant disorder&#xD;
&#xD;
          -  history of hypersensitivity to any drug compound&#xD;
&#xD;
          -  history of stomach or intestinal surgery or resection&#xD;
&#xD;
          -  history of infections of unexplained frequency or severity&#xD;
&#xD;
          -  history of alcoholism or drug addiction within 1 year&#xD;
&#xD;
          -  use of any tobacco- or nicotine-containing products within 6 months&#xD;
&#xD;
          -  use of alcohol-, grapefruit-, caffeine-, or high tyramine-containing foods or&#xD;
             beverages&#xD;
&#xD;
          -  use of any other medications&#xD;
&#xD;
          -  pregnancy, lactation, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Madison, WI, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid phosphate</mesh_term>
    <mesh_term>Tedizolid</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

